Global Benign Prostatic Hyperplasia (BPH) Drugs Market Insights and Forecast to 2027

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Insights and Forecast to 2027

Table of Contents
1 Study Coverage
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type
1.4.2 Alpha-Blocker
1.4.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts 2016-2027
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Estimates and Forecasts 2016-2027
2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Regions by Sales
2.4.1 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Regions by Sales (2016-2021)
2.4.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Regions by Sales (2022-2027)
2.5 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Regions by Revenue
2.5.1 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Regions by Revenue (2016-2021)
2.5.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers
3.1.1 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers by Sales (2016-2021)
3.1.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia (BPH) Drugs Sales in 2020
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers
3.2.1 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia (BPH) Drugs Revenue in 2020
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historical Sales by Type (2016-2021)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Sales by Type (2022-2027)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2027)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historical Revenue by Type (2016-2021)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Revenue by Type (2022-2027)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2016-2027)
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type
4.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2016-2021)
4.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Type (2022-2027)
5 Market Size by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
5.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historical Sales by Application (2016-2021)
5.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Sales by Application (2022-2027)
5.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2027)
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historical Revenue by Application (2016-2021)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Revenue by Application (2022-2027)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2016-2027)
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application
5.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2016-2021)
5.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Application (2022-2027)
6 North America
6.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
6.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2027)
6.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2027)
6.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
6.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2027)
6.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2016-2027)
6.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
6.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2027)
6.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2027)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2027)
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2017-2027)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
7.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2027)
7.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2017-2027)
7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
7.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2027)
7.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
8.1.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2027)
8.1.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2018-2027)
8.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
8.2.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2027)
8.2.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2018-2027)
8.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region
8.3.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2018-2027)
8.3.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2018-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
9.1.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2027)
9.1.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2027)
9.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
9.2.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2027)
9.2.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2027)
9.3 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
9.3.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2027)
9.3.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
6 Middle East and Africa
6.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
6.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2027)
6.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2027)
6.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
6.2.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2027)
6.2.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2016-2027)
6.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
6.3.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2027)
6.3.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2027)
6.3.3 Turkey
6.3.4 Saudi Arabia
6.3.5 UAE
11 Company Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Corporation Information
11.1.2 Eli Lilly Overview
11.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Description
11.1.5 Eli Lilly Related Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Corporation Information
11.2.2 GlaxoSmithKline Overview
11.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Description
11.2.5 GlaxoSmithKline Related Developments
11.3 Astellas Pharma
11.3.1 Astellas Pharma Corporation Information
11.3.2 Astellas Pharma Overview
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Description
11.3.5 Astellas Pharma Related Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Overview
11.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Description
11.4.5 Sanofi Related Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Overview
11.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Description
11.5.5 Pfizer Related Developments
11.6 Abbott
11.6.1 Abbott Corporation Information
11.6.2 Abbott Overview
11.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Description
11.6.5 Abbott Related Developments
11.7 Allergan
11.7.1 Allergan Corporation Information
11.7.2 Allergan Overview
11.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Description
11.7.5 Allergan Related Developments
11.8 TEVA
11.8.1 TEVA Corporation Information
11.8.2 TEVA Overview
11.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
11.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Description
11.8.5 TEVA Related Developments
11.9 Mylan
11.9.1 Mylan Corporation Information
11.9.2 Mylan Overview
11.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
11.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Description
11.9.5 Mylan Related Developments
11.10 Novartis
11.10.1 Novartis Corporation Information
11.10.2 Novartis Overview
11.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
11.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Description
11.10.5 Novartis Related Developments
11.1 Eli Lilly
11.1.1 Eli Lilly Corporation Information
11.1.2 Eli Lilly Overview
11.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Description
11.1.5 Eli Lilly Related Developments
12 Value Chain and Sales Channels Analysis
12.1 Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Analysis
12.2 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
12.4 Benign Prostatic Hyperplasia (BPH) Drugs Sales and Marketing
12.4.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels
12.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
12.5 Benign Prostatic Hyperplasia (BPH) Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
13.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
13.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
13.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
14 Key Findings in The Global Benign Prostatic Hyperplasia (BPH) Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Alpha-Blocker
Table 3. Major Manufacturers of Phosphodiesterase Type-5 Inhibitors
Table 4. Major Manufacturers of Others
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021) & (M Units)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021) & (M Units)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2022-2027)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2016-2021)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2022-2027) & (US$ Million)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2022-2027)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2016-2021) & (M Units)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers (2016-2021)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2021) & (US$ Million)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2016-2021)
Table 19. Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturers 2016-2021 (US$/Unit)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2020)
Table 22. Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 24. Date of Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2022-2027) & (M Units)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2016-2021)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2022-2027)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2021) & (US$ Million)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2022-2027) & (US$ Million)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2016-2021)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2022-2027)
Table 34. Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2016-2021) & (US$/Unit)
Table 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Type (2022-2027) & (US$/Unit)
Table 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2022-2027) & (M Units)
Table 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2016-2021)
Table 39. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2022-2027)
Table 40. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2016-2021) & (US$ Million)
Table 41. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2022-2027) & (US$ Million)
Table 42. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2016-2021)
Table 43. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2022-2027)
Table 44. Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2016-2021) & (US$/Unit)
Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Application (2022-2027) & (US$/Unit)
Table 46. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 47. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2022-2027) & (M Units)
Table 48. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2021) & (US$ Million)
Table 49. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2022-2027) & (US$ Million)
Table 50. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 51. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2022-2027) & (M Units)
Table 52. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2016-2021) & (US$ Million)
Table 53. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2022-2027) & (US$ Million)
Table 54. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 55. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2022-2027) & (M Units)
Table 56. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 57. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2022-2027) & (US$ Million)
Table 58. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 59. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2022-2027) & (M Units)
Table 60. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2021) & (US$ Million)
Table 61. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2022-2027) & (US$ Million)
Table 62. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 63. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2022-2027) & (M Units)
Table 64. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2016-2021) & (US$ Million)
Table 65. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2022-2027) & (US$ Million)
Table 66. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 67. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2022-2027) & (M Units)
Table 68. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 69. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2022-2027) & (US$ Million)
Table 70. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 71. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2022-2027) & (M Units)
Table 72. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2021) & (US$ Million)
Table 73. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2022-2027) & (US$ Million)
Table 74. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 75. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2022-2027) & (M Units)
Table 76. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2016-2021) & (US$ Million)
Table 77. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2022-2027) & (US$ Million)
Table 78. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021) & (M Units)
Table 79. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2022-2027) & (M Units)
Table 80. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 81. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2022-2027) & (US$ Million)
Table 82. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 83. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2022-2027) & (M Units)
Table 84. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2021) & (US$ Million)
Table 85. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2022-2027) & (US$ Million)
Table 86. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 87. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2022-2027) & (M Units)
Table 88. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2016-2021) & (US$ Million)
Table 89. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2022-2027) & (US$ Million)
Table 90. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 91. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2022-2027) & (M Units)
Table 92. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 93. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2022-2027) & (US$ Million)
Table 94. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 95. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2022-2027) & (M Units)
Table 96. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2021) & (US$ Million)
Table 97. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2022-2027) & (US$ Million)
Table 98. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 99. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2022-2027) & (M Units)
Table 100. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2016-2021) & (US$ Million)
Table 101. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2022-2027) & (US$ Million)
Table 102. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 103. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2022-2027) & (M Units)
Table 104. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 105. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2022-2027) & (US$ Million)
Table 106. Eli Lilly Corporation Information
Table 107. Eli Lilly Description and Major Businesses
Table 108. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 109. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 110. Eli Lilly Recent Developments
Table 111. GlaxoSmithKline Corporation Information
Table 112. GlaxoSmithKline Description and Major Businesses
Table 113. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 114. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 115. GlaxoSmithKline Recent Developments
Table 116. Astellas Pharma Corporation Information
Table 117. Astellas Pharma Description and Major Businesses
Table 118. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 119. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 120. Astellas Pharma Recent Developments
Table 121. Sanofi Corporation Information
Table 122. Sanofi Description and Major Businesses
Table 123. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 124. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 125. Sanofi Recent Developments
Table 126. Pfizer Corporation Information
Table 127. Pfizer Description and Major Businesses
Table 128. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 129. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 130. Pfizer Recent Developments
Table 131. Abbott Corporation Information
Table 132. Abbott Description and Major Businesses
Table 133. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 134. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 135. Abbott Recent Developments
Table 136. Allergan Corporation Information
Table 137. Allergan Description and Major Businesses
Table 138. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 139. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 140. Allergan Recent Developments
Table 141. TEVA Corporation Information
Table 142. TEVA Description and Major Businesses
Table 143. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 144. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 145. TEVA Recent Developments
Table 146. Mylan Corporation Information
Table 147. Mylan Description and Major Businesses
Table 148. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 149. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 150. Mylan Recent Developments
Table 151. Novartis Corporation Information
Table 152. Novartis Description and Major Businesses
Table 153. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 154. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 155. Novartis Recent Developments
Table 156. Merck Corporation Information
Table 157. Merck Description and Major Businesses
Table 158. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 159. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 160. Merck Recent Developments
Table 161. Key Raw Materials Lists
Table 162. Raw Materials Key Suppliers Lists
Table 163. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 164. Benign Prostatic Hyperplasia (BPH) Drugs Customers List
Table 165. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
Table 166. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
Table 167. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
Table 168. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2020 & 2027
Figure 3. Alpha-Blocker Product Picture
Figure 4. Phosphodiesterase Type-5 Inhibitors Product Picture
Figure 5. Others Product Picture
Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020 & 2027
Figure 7. Hospitals
Figure 8. Drugstores
Figure 9. Others
Figure 10. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2027 (M Units)
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2016-2027 (US$ Million)
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in Percentage: 2020 Versus 2027
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
Figure 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2022-2027)
Figure 17. North America Benign

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Histone Deacetylase (HDAC) Inhibitors Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 87

The global Histone Deacetylase (HDAC) Inhibitors market was valued at US$ 615.2 million in 2023 and is anticipated to reach US$ 1223.2 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. North American market for Histone Deacetylase (HDAC) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Histone Deacetylase (HDAC) Inhibitor......

Global Esomeprazole Magnesium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74

The global Esomeprazole Magnesium market was valued at US$ 5287 million in 2023 and is anticipated to reach US$ 9451.5 million by 2030, witnessing a CAGR of 8.3% during The forecast period 2024-2030. North American market for Esomeprazole Magnesium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Esomeprazole Magnesium is estimated to increase from $ million in 2......

Global Combination Therapy Drug Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Combination Therapy Drug market was valued at US$ 105 million in 2023 and is anticipated to reach US$ 166.7 million by 2030, witnessing a CAGR of 4.1% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is......

Global Axitinib Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 68

The global Axitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The......

Global Lyme Disease Vaccine Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 70

The lyme disease vaccine can reduce lyme disease incidence, reduce symptoms and reduce mortality. Lyme disease is a tick-borne infection of spirochete, a natural disease caused by borrelia burgdorferi. The global Lyme Disease Vaccine market was valued at US$ 257 million in 2023 and is anticipated to reach US$ 763 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at......

Global Transdermal Absorption Patch Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Transdermal Absorption Patch market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Transdermal Absorption Patch is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Transdermal Absorption Patch is estimated to increase from $ million i......

Global Ketoprofen Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

Ketoprofen patch, indications for The treatment of symptoms caused by The following diseases: rheumatoid arthritis and rheumatoid arthritis The global Ketoprofen Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Ketoprofen Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast per......

Global Methyl Salicylate Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 82

The global Methyl Salicylate Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to......

Global Diclofenac Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Diclofenac Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs